Myleus Biotecnologia
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Myleus Biotecnologia - overview
Established
2010
Location
Belo Horizonte, Minas Gerais, Brazil
Primary Industry
Biopolymers
About
Myleus Biotecnologia is a Brazilian biotechnology company focused on delivering innovative solutions to improve operational efficiencies in various applications, addressing specific challenges within its target market. Founded in 2010 in Belo Horizonte, Brazil, Myleus Biotecnologia specializes in biotechnological advancements. The company has undergone significant strategic pivots to enhance its product offerings. CEO Marcela Drummond leads the firm, which has completed two funding deals, with its most recent deal occurring on October 11, 2016.
This funding round was aimed at supporting new initiatives as the company continues to evolve its operational focus. Myleus Biotecnologia’s primary offerings include a suite of innovative biotechnological solutions aimed at enhancing operational efficiency and improving user experience. The core product line focuses on biotechnological solutions tailored for businesses and individual consumers, particularly in the healthcare and pharmaceutical sectors. The products are marketed across North America, Europe, and Asia, allowing for a broad market presence that addresses the diverse needs of its clientele.
Myleus Biotecnologia generates revenue through a structured model encompassing diverse transaction types tailored to its clients. Revenue primarily derives from direct sales to consumers and B2B partnerships, allowing for flexible engagement with both individual and corporate clients. Typical transactions occur through one-time purchases, with flagship products positioned at the center of these engagements. This structured pricing approach enhances customer satisfaction by providing scalable options aligned with client needs.
Myleus Biotecnologia aims to launch new biotechnological products by utilizing data obtained from its previous funding round. The company plans to expand its market reach into Latin America and Europe by 2025. The venture financing raised in October 2016 will support these initiatives, allowing the firm to enhance its product development and geographic outreach.
Current Investors
Antera Asset Management, Fundepar
Primary Industry
Biopolymers
Sub Industries
Biopolymers
Website
www.myleus.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Myleus Biotecnologia - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.